Need of Beta 3 Agonist in Today's World as Oral Hypoglycaemic and Antiobesity

Lowering blood glucose levels in case of patients suffering from type 1 diabetes plays an important role in decreasing the risk of long-term complications. In clinical scenario, fully fledged insulin therapy is often limited by the increased risk hypoglycemia which is severe in nature. Thus, nowadays newer and safer regimens of oral hypoglycemic drugs are introduced out of which beta 3 adrenergic receptor agonists are showing a promising future in combating the menace of hyperglycemia or diabetes mellitus paired with obesity.